Kura Oncology (KURA) Gains Momentum as Barclays Sees Significant Potential in Ziftomenib Approval

Kura Oncology Inc. (NASDAQ:KURA) is one of the stocks that will double in 2026. On November 24, Barclays analyst Etzer Darout raised the firm’s price target on Kura Oncology to $28 from $11 and maintained an Overweight rating on the shares. This decision was made as Barclays saw potential in the company’s ziftomenib approval. This approval came earlier, on November 18, when Kura Oncology and Kyowa Kirin Co. Ltd. announced that the US FDA granted full approval to KOMZIFTI (ziftomenib) for the treatment of ...